Hepalink begins phase 1 trial for cancer drug

Shenzhen Hepalink Pharmaceutical Group announced the first patient enrollment and dosing in its Phase I clinical trial for H1710 injection on July 18, 2025.

H1710 is a heparin derivative and heparanase inhibitor targeting advanced solid tumors, representing a novel mechanism with no approved products currently existing globally.

The dose-escalation study will evaluate safety, tolerability, and preliminary anti-tumor activity across 36 patients at three research centers.